NCT06221800Recruiting
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
A Pilot Study to Assess the Diversity of Gut Microbiome in Metastatic Non-Small Cell Lung Cancer (NSCLC) in Correlation to Treatment Effects and Adverse Effects
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 82 (estimated)
- First submitted
- 15 Jan 2024
- Start date
- 31 Jan 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- University of California, Irvine
- Diseases
- Lung cancer
- NCT number
- NCT06221800
What you commit to
- Study type: Observational
- Planned participants: 82
- From 31 Jan 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Those subjects who are determined clinically unstable of the participation of this study as determined by the PI or treating physician will be excluded and asked to focus on their treatment.
Who the study is looking for
- 1\. Advanced/Metastatic non-small cell lung cancer NSCLC patients.
- 2\. The patient himself/herself must be 18 years of age on day of signing informed consent.
- 3\. The subject has signed the informed consent form.
- 4\. The patient must be eligible to receive FDA approved and non-approved PD1 inhibitors (i.e. pembrolizumab, nivolumab) or PDL1 inhibitor (i.e. atezolizumab, durvalumab) either single agent or as combination therapy with chemotherapy, or be eligible to receive FDA approved and non-approved tyrosine kinase inhibitors.
- 5\. The subject will be registered upon submission of the samples. When submitted on separate dates, the submission occurring later will be considered the date of registration
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chao Family Comprehensive Cancer Center, University of California, Irvine Coordinator of this site? Confirm its status | Orange | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.